Home>About Us>Accolades
Company Profile Social Responsibility Scientific Advisory Board The core team The board of directors Patient Care Accolades
Accolades
Recognition obtained
Academic AchievementsCorporate Honors
2021/2022
Vebreltinib received recognition for breakthrough therapy by National Medical Products Administration
Vebreltinib received orphan drug certification from FDA
2018
Vebreltinib precision treatment for glioma named "China's Top 10 Advances in Life Sciences in 2018" by China Association for Science and Technology
Top international medical publication "Cell"
Publication of operating mechanism and results of Phase I clinical trial for Vebreltinib treatment for glioma
2016
Purun'ao became a member of the inaugural batch of companies in Beijing Biopharmaceutical Industry Breakthrough Development Project (also known as G20 Project)
2014
Dr. Shi Hepeng and his research team selected for "100 Leading Science and Technology Talents Development Project of Beijing".
2015
Dr. Shi Hepeng nominated for "Leading Innovation and Entrepreneurial Talent Support Plan" by Beijing Municipal Human Resources and Social Security Bureau.
China headquarters: 5th Floor, Block B, Wangjing Science and Technology Park, Lize Middle 2nd Road, Chaoyang District, Beijing.
American branch: 850 New Burton Road, Suite 201, City of Dover,County of Kent, State of Delaware
Phone: 010- 84148921
Email:
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.

京ICP备2020040683号-2